Exercise4

BioStem Technologies, Inc.

Total Value

$1.0M

Filing Date

Oct 9, 2026

1 transactions

Trade Summary

On Oct 7, 2026, SMITH-VAN VURST ANDREW, Insider, reported $1.0M of BioStem Technologies, Inc. (BSEM) across 1 transactions. The filing covers Common Stock and reflects balanced net activity of $0. Reported prices ranged from $2.00. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.

Insider Information

Name: SMITH-VAN VURST ANDREW
Role: Insider
Location: POMPANO BEACH, FL

Filing Details

Filing Date: Oct 9, 2026
Transaction Date: Oct 7, 2026
Accession Number: 0001193125-26-419153
Form Type: 4

Non-Derivative Transactions

Date	Security	Shares	Price	Type	Value
Oct 7, 2026	Common Stock	250,000	$2.00	Exercise	$500.0K

Derivative Transactions

Date	Security	Shares	Exercise Price	Type	Value
Oct 7, 2026	BSEM derivative	250,000	$2.00	Exercise	$500.0K

Want live alerts when SMITH-VAN VURST ANDREW trades again?

Download Insider Trades to track BSEM, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.

iOS App Android App

Footnotes

(F1)The Series A-1 Convertible Preferred Shares are convertible in whole into shares of the Issuer's Common Stock on a one-to-one basis at the option of a majority of the holders of Series A-1 Convertible Preferred Shares.
(F2)The Series A-1 Convertible Preferred Shares have no expiration date.
(F3)Due to an administrative error, the Series A-1 Convertible Preferred Shares were inadvertently omitted from the Reporting Person's Form 3 filed on August 14, 2026.
(F4)These options are fully vested and exercisable.
(F5)These options vest according to the following schedule: 33% vested on March 17, 2026, the one-year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
(F6)These options vest according to the following schedule: 33% will vest on October 13, 2026, the one-year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
(F7)These options vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
(F8)Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
(F9)These restricted stock units will vest in equal quarterly installments over three years from the grant date (September 15, 2024).
(F10)These restricted stock units vest according to the following schedule: 33% vested on March 17, 2026, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period.
(F11)These restricted stock units vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SMITH-VAN VURST ANDREW

(Last)

(First)

(Middle)

C/O BIOSTEM TECHNOLOGIES, INC.

2836 CENTER PORT CIRCLE

(Street)

POMPANO BEACH

33064

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
BioStem Technologies, Inc. [ BSEM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/07/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/07/2026		M		250,000	A	$2	1,789,809	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Series A-1 Convertible Preferred Shares	⁽¹⁾							05/23/2016	⁽²⁾	Common Stock	100		100⁽³⁾	D
Options (Right to Buy)	$2	10/07/2026		M			250,000	⁽⁴⁾	10/24/2032	Common Stock	250,000	$0.00	2,000,000	D
Options (Right to Buy)	$10.05							⁽⁵⁾	03/17/2035	Common Stock	114,314		114,314	D
Options (Right to Buy)	$10.05							⁽⁶⁾	10/13/2035	Common Stock	23,246		23,246	D
Options (Right to Buy)	$5.5							⁽⁷⁾	02/11/2036	Common Stock	253,304		253,304	D
Restricted Stock Units	⁽⁸⁾							⁽⁹⁾	⁽⁹⁾	Common Stock	30,487		30,487	D
Restricted Stock Units	⁽⁸⁾							⁽¹⁰⁾	⁽¹⁰⁾	Common Stock	57,442		57,442	D
Restricted Stock Units	⁽⁸⁾							⁽¹¹⁾	⁽¹¹⁾	Common Stock	209,091		209,091	D

Explanation of Responses:

1. The Series A-1 Convertible Preferred Shares are convertible in whole into shares of the Issuer's Common Stock on a one-to-one basis at the option of a majority of the holders of Series A-1 Convertible Preferred Shares.

2. The Series A-1 Convertible Preferred Shares have no expiration date.

3. Due to an administrative error, the Series A-1 Convertible Preferred Shares were inadvertently omitted from the Reporting Person's Form 3 filed on August 14, 2026.

4. These options are fully vested and exercisable.

5. These options vest according to the following schedule: 33% vested on March 17, 2026, the one-year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.

6. These options vest according to the following schedule: 33% will vest on October 13, 2026, the one-year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.

7. These options vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.

8. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

9. These restricted stock units will vest in equal quarterly installments over three years from the grant date (September 15, 2024).

10. These restricted stock units vest according to the following schedule: 33% vested on March 17, 2026, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period.

11. These restricted stock units vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period.

	/s/ Katherine Gorrell, Attorney-in-Fact	10/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Form 4 as rendered by the SEC from accession 0001193125-26-419153.

BioStem Technologies, Inc.

Trade Summary

Company Information

Insider Information

Filing Details

Non-Derivative Transactions

Derivative Transactions

Want live alerts when SMITH-VAN VURST ANDREW trades again?

Footnotes

SEC Form 4

SEC Filing

SEC Form 4